{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:49:24Z","timestamp":1778680164259,"version":"3.51.4"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.phrs.2019.104394","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T10:59:02Z","timestamp":1567853942000},"page":"104394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Psoriatic arthritis: From pathogenesis to pharmacologic management"],"prefix":"10.1016","volume":"148","author":[{"given":"Rossella","family":"Talotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignazio Francesco","family":"Masala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.phrs.2019.104394_bib0005","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/BOR.0b013e32832c7832","article-title":"Psoriatic arthritis assessment and treatment update","volume":"21","author":"Mease","year":"2009","journal-title":"Curr. Opin. Rheumatol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104394_bib0010","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of spondylo arthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.phrs.2019.104394_bib0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11926-013-0377-4","article-title":"Mechanistic insights from animal models of psoriasis and psoriatic arthritis","volume":"15","author":"Weitz","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"issue":"4","key":"10.1016\/j.phrs.2019.104394_bib0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.autrev.2014.11.012","article-title":"T cell responses in psoriasis and psoriatic arthritis","volume":"14","author":"Diani","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.phrs.2019.104394_bib0025","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.jisp.2018.09.005","article-title":"Expanded genome-wide association study meta-analysis of psoriasis expands the catalog of common psoriasis-associated variants","volume":"19","author":"Elder","year":"2018","journal-title":"J. Invest. Dermatol. Symp. Proc."},{"key":"10.1016\/j.phrs.2019.104394_bib0030","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1038\/ncomms8001","article-title":"Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci","volume":"6","author":"Tsoi","year":"2015","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.phrs.2019.104394_bib0035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways","volume":"41","author":"Nair","year":"2009","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.phrs.2019.104394_bib0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/gene.2009.11","article-title":"Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis","volume":"10","author":"Elder","year":"2009","journal-title":"Genes Immun."},{"issue":"6","key":"10.1016\/j.phrs.2019.104394_bib0045","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ejhg.2014.172","article-title":"Fine mapping of eight psoriasis susceptibility loci","volume":"23","author":"Das","year":"2015","journal-title":"Eur. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.phrs.2019.104394_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001338","article-title":"A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci","volume":"4","author":"Liu","year":"2008","journal-title":"PLoS Genet."},{"issue":"6","key":"10.1016\/j.phrs.2019.104394_bib0055","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","article-title":"Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture","volume":"97","author":"Stuart","year":"2015","journal-title":"Am. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.phrs.2019.104394_bib0060","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/rheumatology\/kev296","article-title":"HLA-B27 and psoriatic disease: a modern view of an old relationship","volume":"55","author":"Queiro","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.phrs.2019.104394_bib0065","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-015-0640-3","article-title":"Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype","volume":"17","author":"FitzGerald","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"8","key":"10.1016\/j.phrs.2019.104394_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105684","article-title":"HLA-B27 and human \u03b22-microglobulin affect the gut microbiota of transgenic rats","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.phrs.2019.104394_bib0075","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2217\/bmm.14.76","article-title":"Proteomics focusing on immune markers in psoriatic arthritis","volume":"9","author":"Caruntu","year":"2015","journal-title":"Biomark. Med."},{"issue":"3","key":"10.1016\/j.phrs.2019.104394_bib0080","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00403-016-1620-4","article-title":"Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis","volume":"308","author":"Smith","year":"2016","journal-title":"Arch. Dermatol. Res."},{"issue":"6","key":"10.1016\/j.phrs.2019.104394_bib0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128262","article-title":"Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis","volume":"10","author":"Dolcino","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.phrs.2019.104394_bib0090","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/rheumatology\/ket319","article-title":"The bacterial skin microbiome in psoriatic arthritis, an unexplored link in pathogenesis: challenges and opportunities offered by recent technological advances","volume":"53","author":"Castelino","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.phrs.2019.104394_bib0095","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1002\/art.38773","article-title":"ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice","volume":"66","author":"Rehaume","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104394_bib0100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11926-013-0407-2","article-title":"The microbiome and psoriatic arthritis","volume":"16","author":"Eppinga","year":"2014","journal-title":"Curr. Rheumatol. Rep."},{"issue":"5","key":"10.1016\/j.phrs.2019.104394_bib0105","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11926-011-0198-2","article-title":"Mucosal inflammation in spondylarthritides: past, present, and future","volume":"13","author":"Van Praet","year":"2011","journal-title":"Curr. Rheumatol. Rep."},{"issue":"5","key":"10.1016\/j.phrs.2019.104394_bib0110","first-page":"924","article-title":"Patients with psoriatic arthritis have an increased number of lymphocytes in the duodenal mucosa in comparison with patients with psoriasis vulgaris","volume":"33","author":"Lindqvist","year":"2006","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104394_bib0115","first-page":"1241","article-title":"Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms","volume":"27","author":"Scarpa","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104394_bib0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3899\/jrheum.120233","article-title":"The synovio-entheseal complex and its role in tendon and capsular associated inflammation","volume":"89","author":"McGonagle","year":"2012","journal-title":"J. Rheumatol. Suppl."},{"issue":"9134","key":"10.1016\/j.phrs.2019.104394_bib0125","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(97)12004-9","article-title":"Classification of inflammatory arthritis by enthesitis","volume":"352","author":"McGonagle","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.phrs.2019.104394_bib0130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.semarthrit.2013.04.005","article-title":"Enthesitis in psoriatic arthritis","volume":"43","author":"Sakkas","year":"2013","journal-title":"Semin. Arthritis Rheum."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2019.104394_bib0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2009.03363.x","article-title":"Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease","volume":"23","author":"McGonagle","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"9","key":"10.1016\/j.phrs.2019.104394_bib0140","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/rheumatology\/ket407","article-title":"Spondyloarthritis: from unifying concepts to improved treatment","volume":"53","author":"Baeten","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.phrs.2019.104394_bib0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014108","article-title":"Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis","volume":"5","author":"Res","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104394_bib0150","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7692024","article-title":"T helper cell subsets in clinical manifestations of psoriasis","volume":"2016","author":"Diani","year":"2016","journal-title":"J. Immunol. Res."},{"issue":"2","key":"10.1016\/j.phrs.2019.104394_bib0155","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.semarthrit.2013.04.006","article-title":"Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics","volume":"43","author":"van den Berg","year":"2013","journal-title":"Semin. Arthritis Rheum."},{"issue":"4\u20135","key":"10.1016\/j.phrs.2019.104394_bib0160","first-page":"496","article-title":"The IL-23\/IL-17 axis in psoriatic arthritis","volume":"13","author":"Mellins","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"Jun (3)","key":"10.1016\/j.phrs.2019.104394_bib0165","first-page":"246","article-title":"Mirshafiey A.Th22 cells contribution in immunopathogenesis of rheumatic diseases","volume":"14","author":"Azizi","year":"2015","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"10.1016\/j.phrs.2019.104394_bib0170","series-title":"Th9 Cells in Inflammatory Cascades of Autoimmune Arthritis. ACR Abstracts","author":"Raychaudhuri","year":"2014"},{"issue":"8","key":"10.1016\/j.phrs.2019.104394_bib0175","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/art.39649","article-title":"Interleukin-9 overexpression and Th9 polarization characterize the inflamed gut, the synovial tissue, and the peripheral blood of patients with psoriatic arthritis","volume":"68","author":"Ciccia","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"10.1016\/j.phrs.2019.104394_bib0180","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrgastro.2014.108","article-title":"IBD. TH9 cells might have a role in the pathogenesis of ulcerative colitis","volume":"11","author":"Leake","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104394_bib0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00281-016-0606-9","article-title":"IL-9 and Th9 in parasite immunity","volume":"39","author":"Licona-Lim\u00f3n","year":"2017","journal-title":"Semin. Immunopathol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104394_bib0190","first-page":"609","article-title":"Association of rheumatoid factor and uric acid with psoriatic arthritis: a review","volume":"23","author":"Khondker","year":"2014","journal-title":"Mymensingh Med. J."},{"issue":"10","key":"10.1016\/j.phrs.2019.104394_bib0195","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/rheumatology\/kew229","article-title":"Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis","volume":"55","author":"Behrens","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.phrs.2019.104394_bib0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115424","article-title":"Crossreactive autoantibodies directed against cutaneous and joint antigens are present in psoriatic arthritis","volume":"9","author":"Dolcino","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2019.104394_bib0205","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/art.39515","article-title":"Activation-induced killer cell immunoglobulin-like receptor 3DL2 binding to HLA-B27 licenses pathogenic t cell differentiation in spondyloarthritis","volume":"68","author":"Ridley","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104394_bib0210","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/BOR.0b013e3283620163","article-title":"The role of natural killer cells, gamma delta T-cells and other innate immune cells in spondyloarthritis","volume":"25","author":"Al-Mossawi","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104394_bib0215","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.autrev.2012.10.002","article-title":"Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways","volume":"12","author":"Chimenti","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.phrs.2019.104394_bib0220","first-page":"5","article-title":"\u201cToll\u201d for Th17 expansion","volume":"88","author":"Davila","year":"2010","journal-title":"JLB"},{"issue":"3","key":"10.1016\/j.phrs.2019.104394_bib0225","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2249.2011.04535.x","article-title":"Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes","volume":"167","author":"Ozkurede","year":"2012","journal-title":"Clin. Exp. Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104394_bib0230","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10409238.2015.1033511","article-title":"Advances in Toll-like receptor biology: modes of activation by diverse stimuli","volume":"50","author":"Bryant","year":"2015","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104394_bib0235","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/1573397112666161230125317","article-title":"Biological agents in rheumatoid arthritis: a cross-link between immune tolerance and immune surveillance","volume":"14","author":"Talotta","year":"2018","journal-title":"Curr. Rheumatol. Rev."},{"issue":"3","key":"10.1016\/j.phrs.2019.104394_bib0240","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/pcmr.12470","article-title":"Melanocytes in psoriasis: convicted culprit or bullied bystander?","volume":"29","author":"Strassner","year":"2016","journal-title":"Pigment Cell Melanoma Res."},{"issue":"5","key":"10.1016\/j.phrs.2019.104394_bib0245","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/mmy\/myu026","article-title":"Melanocytes and melanin represent a first line of innate immunity against Candida albicans","volume":"52","author":"Tapia","year":"2014","journal-title":"Med. Mycol."},{"key":"10.1016\/j.phrs.2019.104394_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/710928","article-title":"Metabolic syndrome in rheumatoid arthritis","author":"Ferraz-Amaro","year":"2013","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.phrs.2019.104394_bib0255","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/ar2515","article-title":"Vascular involvement in rheumatic diseases: \u201cvascular rheumatology\u201d","volume":"10","author":"Szekanecz","year":"2008","journal-title":"Arthitis Res. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2019.104394_bib0260","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7150\/ijms.7.284","article-title":"Pathogenic mechanisms shared between psoriasis and cardiovascular disease","volume":"7","author":"Ghazizadeh","year":"2010","journal-title":"Int. J Med. Sci."},{"issue":"10","key":"10.1016\/j.phrs.2019.104394_bib0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046740","article-title":"Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions","volume":"7","author":"Xue","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104394_bib0270","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1529-8019.2008.01217.x","article-title":"Effects of tumor necrosis factor-a blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis","volume":"22","author":"Channual","year":"2009","journal-title":"Dermatol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.104394_bib0275","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/kes242","article-title":"Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management","volume":"52","author":"Russolillo","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.phrs.2019.104394_bib0280","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.reuma.2015.12.005","article-title":"Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug?","volume":"12","author":"Gal\u00edndez","year":"2016","journal-title":"Reumatol. Clin."},{"issue":"4","key":"10.1016\/j.phrs.2019.104394_bib0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152786","article-title":"Adipocytes as a link between gut microbiota-derived flagellin and hepatocyte fat accumulation","volume":"11","author":"Munukka","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2019.104394_bib0290","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/ard.61.4.298","article-title":"Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors","volume":"61","author":"Mease","year":"2002","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.phrs.2019.104394_bib0295","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00296-014-3006-2","article-title":"Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety","volume":"34","author":"Lemos","year":"2014","journal-title":"Rheumatol. Int."},{"issue":"9894","key":"10.1016\/j.phrs.2019.104394_bib0300","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2019.104394_bib0305","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.phrs.2019.104394_bib0310","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.phrs.2019.104394_bib0315","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104394_bib0320","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104394_bib0325","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"10136","key":"10.1016\/j.phrs.2019.104394_bib0330","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104394_bib0335","article-title":"Tildrakizumab: a review of phase II and III clinical trials","author":"Kolli","year":"2018","journal-title":"Ann. Pharmacother."},{"issue":"0","key":"10.1016\/j.phrs.2019.104394_bib0340","first-page":"1198","article-title":"Anti-cytokine therapy for psoriasis - not only TNF-\u03b1 blockers. Overview of reports on the effectiveness of therapy with IL\u201312\/IL-23 and T and B lymphocyte inhibitors","volume":"70","author":"Wcis\u0142o-Dziadecka","year":"2016","journal-title":"Postepy Hig. Med. Dosw. (Online)"},{"key":"10.1016\/j.phrs.2019.104394_bib0345","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.2147\/DDDT.S167149","article-title":"Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis","volume":"12","author":"Haugh","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.104394_bib0350","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40744-016-0031-5","article-title":"Secukinumab: a new treatment option for psoriatic arthritis","volume":"3","author":"Mease","year":"2016","journal-title":"Rheumatol. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2019.104394_bib0355","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104394_bib0360","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2147\/DDDT.S113683","article-title":"Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy","volume":"11","author":"Roman","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.phrs.2019.104394_bib0365","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3899\/jrheum.150643","article-title":"Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis","volume":"93","author":"Atzeni","year":"2015","journal-title":"J. Rheumatol. Suppl."},{"issue":"3","key":"10.1016\/j.phrs.2019.104394_bib0370","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bjd.13012","article-title":"Partial clinical response to anakinra in severe palmoplantar pustular psoriasis","volume":"171","author":"Tauber","year":"2014","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104394_bib0375","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjd.14685","article-title":"Successful resposne in a case of severe pustular psoriasis after interleukin-1b inhibition","volume":"176","author":"Skendros","year":"2017","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104394_bib0380","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00296-016-3436-0","article-title":"Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies","volume":"36","author":"Elyoussfi","year":"2016","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.phrs.2019.104394_bib0385","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40265-015-0439-1","article-title":"Apremilast: a review in psoriasis and psoriatic arthritis","volume":"75","author":"Deeks","year":"2015","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.phrs.2019.104394_bib0390","article-title":"The role of a non-canonical JAK-STAT pathway in IFN therapy of poxvirus infection and multiple sclerosis: An example of Occam\u2019s Broom?","volume":"2","author":"Ahmed","year":"2013","journal-title":"JAKSTAT"},{"issue":"2","key":"10.1016\/j.phrs.2019.104394_bib0395","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/ard.2005.037929","article-title":"Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis","volume":"65","author":"Walker","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.phrs.2019.104394_bib0400","first-page":"318","article-title":"The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104394_bib0405","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104394_bib0410","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104394_bib0415","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special article: 2018 American college of rheumatology\/national psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.phrs.2019.104394_bib0420","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.phrs.2019.104394_bib0425","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104394_bib0430","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3899\/jrheum.150642","article-title":"The role of tumor necrosis factor-\u03b1 blockers in psoriatic disease. Therapeutic options in psoriatic arthritis","volume":"93","author":"Addimanda","year":"2015","journal-title":"J. Rheumatol. Suppl."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819310710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819310710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:05:17Z","timestamp":1760911517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819310710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":86,"alternative-id":["S1043661819310710"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104394","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriatic arthritis: From pathogenesis to pharmacologic management","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104394"}}